Trastuzumab

Red

Brand Name(s):Herceptin
Ontruzant
Herzuma
Kanjinti
Trazimera

Indication:HER-2 positive breast cancer following surgery, chemotherapy or radiotherapy

Rationale:1,2,3,8

Considered:Aug-06

Review Date:Mar-24

Comments:
NICE TA 371
Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane.

Trastuzumab is not recommended, within its marketing authorisation, for treating adults with humanepidermal growth factor 2 positive unresectable locally advanced or metastatic breast cancer previously with trastuzumab and a taxane.

December 2015
…………………………
1.1 Lapatinib in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women with metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).
1.2 Trastuzumab in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women with metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
1.3 Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor that is not recommended according to 1.1 or 1.2 should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
NICE Guidance TA257 June 2012

In patients with HER2-positive invasive breast cancer trastuzumab is a routine adjuvant therapy, where appropriate, following surgery, chemotherapy and radiotherapy.
The recommended scheduling at present is 3-weekly treatment for 1 year but there may be more effective and cost-effective regimens.